FDA approves Gilead cancer gene therapy; price set at $373,000
(Reuters) - U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Gene Therapy | Genetics | Health | Lymphoma | Pharmaceuticals | Science